Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial.
Atefeh VaeziMehrzad SalmasiForogh SoltaninejadMehrdad SalahiShaghayegh Haghjooy JavanmardBabak AmraPublished in: Advances in respiratory medicine (2023)
Our study shows that Favipiravir did not reduce the hospitalization rate of mild to moderate COVID-19 patients in outpatient settings.